Finance Minister Nirmala Sitharaman highlighted the transformative potential of biologic medicines during her Union Budget 2026 speech, stating, “Biologic medicines are key to longevity and quality of life at affordable costs.” This visionary initiative positions India as a global biopharma manufacturing powerhouse.
₹10,000 Crore Biopharma Shakti Mission
The FM proposed the Biopharma Shakti Mission with a robust outlay of ₹10,000 crores over the next five years to cultivate a comprehensive ecosystem for domestic production of biologics and biosimilars. This strategic push will enhance manufacturing capabilities, reduce import dependency, and ensure accessible life-saving treatments for millions.
Expanding NIPER Infrastructure
A key pillar includes establishing three new National Institutes of Pharmaceutical Education and Research (NIPERs) alongside upgrading seven existing ones, fostering cutting-edge research and skilled talent development. These expansions will drive innovation in biopharma, aligning with India’s ambition to lead global pharmaceutical standards.
Clinical Trials and Regulatory Strengthening
The mission envisions a network of 1,000 accredited India clinical trials sites to accelerate drug development while upholding safety. Strengthening the Central Drugs Standard Control Organisation (CDSCO) through dedicated scientific reviews and specialist teams will expedite approvals, meeting international benchmarks and boosting export potential.
This forward-thinking blueprint promises affordable biologics, job creation, and a healthier future, reinforcing India’s healthcare self-reliance amid robust economic growth projections.
